Clinical Trials Logo

Huntington Disease clinical trials

View clinical trials related to Huntington Disease.

Filter by:

NCT ID: NCT05808153 Recruiting - Huntington Disease Clinical Trials

Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression

I2BIO-HD
Start date: March 21, 2024
Phase: N/A
Study type: Interventional

Intro Huntington's disease (HD) patients suffer from motor, cognitive and behavioral impairments, with heterogeneous phenotypes and variable time course. This leads to a high variance of HD markers, none of which is currently sensitive enough to 1) measure disease progression from small cohort data, 2) predict disease entry in carriers of the HD mutation (during the prodromal phase or in patients considered asymptomatic: pre-HD patients), and 3) measure a significant evolution of the state of pre-HD patients over a time window compatible with the realization of clinical trials (about 2/3 years). Moreover, the markers of HD do not allow a fine stratification of the patients. Hypothesis/Objective Our objectives are 1) to evaluate the sensitivity of new markers and assessment tools for symptomatic (HD) and presymptomatic (pre-HD) patients, 2) to define a model of disease progression, and 3) to establish an enrichment strategy to improve patient selection for future therapeutic trials. Method We will evaluate newly developed cognitive tests, multimodal imaging techniques, biological markers and use innovative statistical approaches. We will follow 60 patients with the mutation responsible for MH (40 presymptomatic pre-MH patients, 20 symptomatic MH patients) and 20 healthy volunteers (controls) over a 24-month period.

NCT ID: NCT05773196 Recruiting - Huntington Disease Clinical Trials

Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study

SAN-09611
Start date: March 14, 2023
Phase:
Study type: Observational

OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease. The secondary study objective is to create a biorepository that can be used to identify disease associated biomarkers and potential targets with immune and multi-omics profiling. The disease sample collection and analysis will be the foundation for an extensive network of biospecimen access and linked datasets for future translational research.

NCT ID: NCT05707663 Recruiting - Clinical trials for Juvenile-Onset Huntington Disease

Longitudinal Assessment of Brain Structure and Function in Juvenile-onset Huntington's Disease

Start date: April 17, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about brain development in Juvenile-onset Huntington's Disease (JoHD). The main questions it aims to answer are: - Is brain development different in JoHD than Adult-onset Huntington's Disease (AoHD)? - Can reliable biomarkers for JoHD be found in brain structure and function? Participants will be asked to complete cognitive tests, behavioral assessments, physical and neurologic evaluation, and MRI. Data collected will be compared to populations who are at-risk for HD and who have been diagnosed with HD as adults.

NCT ID: NCT05686551 Recruiting - Huntington Disease Clinical Trials

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.

Start date: February 3, 2023
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease.

NCT ID: NCT05655520 Recruiting - Huntington Disease Clinical Trials

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Start date: December 14, 2022
Phase: Phase 3
Study type: Interventional

The primary purpose of the study is to evaluate the safety and tolerability of SAGE-718 softgel lipid capsule in participants with Huntington's Disease (HD)

NCT ID: NCT05534139 Recruiting - Huntington Disease Clinical Trials

Clinicopathological MRI and CSF Correlates in Huntington's Disease.

Start date: August 11, 2021
Phase:
Study type: Observational

In this study the investigators will link brain iron levels obtained from quantitative susceptibility maps of HD patients with specific and well-known clinical CSF markers for iron accumulation, neurodegeneration and neuroinflammation. The relationship between iron accumulation and neuroinflammation, and the clinical and genetic characteristics of HD will be investigated. This will provide an important basis for the evaluation of brain iron levels as an imaging biomarker for disease state in HD and their relationship with the salient pathomechanisms of the disease.

NCT ID: NCT05358717 Recruiting - Huntington Disease Clinical Trials

A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)

Start date: April 25, 2022
Phase: Phase 2
Study type: Interventional

The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.

NCT ID: NCT05326451 Recruiting - Huntington Disease Clinical Trials

Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease

Start date: June 21, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to assess feasibility, acceptability, and safety of providing transcranial direct current stimulation( tDCS) to Huntingtons Disease (HD) patients in the early to middle stages and to assess the efficacy of tDCS for HD-related behavioral, cognitive and other symptoms

NCT ID: NCT05270681 Recruiting - Huntington Disease Clinical Trials

Move to Improve: Telehealth Exercise to Music for HD

MtI
Start date: November 8, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if a movement to music exercise program delivered via telehealth is feasible and safe for individuals with neurodegenerative disease and their caregivers (Aim 1). A secondary aim will be to determine if a movement to music exercise program delivered via telehealth improves balance, cognition, mobility, and quality of life (Aim 2).

NCT ID: NCT05243017 Recruiting - Huntington Disease Clinical Trials

Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease

Start date: October 7, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is the second study of AMT-130 in patients with early manifest HD and is designed as part of an integrated two-study phase I/II program under a single data safety monitoring board (DSMB) with staggered enrollment based upon continued demonstration of safety of AMT-130 administration. Cohort 3 participants will receive either high or low dose (1:1 randomization). Participants enrolled in Cohort 3 will also receive an immunosuppression regimen consisting of dexamethasone, sirolimus, and rituximab.